Opus Genetics (NASDAQ: IRD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Opus Genetics reported 24 open-market sales of 6,476,531 shares ($19.7m) and 2 open-market purchases of 164,000 shares ($323,890), by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 3 November 2026 | Magrath George | Chief Executive Officer | Open-market sale | −28,258 | $3.90 | 2,010,636 | Form 4 |
| 23 October 2026 | Magrath George | Chief Executive Officer | Open-market sale | −9,591 | $3.59 | 2,038,894 | Form 4 |
| 23 October 2026 | Gagnon Robert E. | Chief Financial Officer | Open-market sale, 10b5-1 plan | −14,000 | $3.55 | 542,375 | Form 4 |
| 23 October 2026 | Yerxa Benjamin R | President | Open-market sale | −7,669 | $3.55 | 696,437 | Form 4 |
| 23 October 2026 | Yerxa Benjamin R | President | Open-market sale | −25,520 | $3.53 | 670,917 | Form 4 |
| 23 October 2026 | Schachle Joseph K | Chief Operating Officer | Open-market sale | −4,767 | $3.57 | 286,673 | Form 4 |
| 30 September 2026 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open-market sale | −556,000 | $4.96 | 3,236,171 | Form 4 |
| 9 September 2026 | Magrath George | Chief Executive Officer | Option exercise | +392,157 | $1.15 | 2,124,026 | Form 4 |
| 9 September 2026 | Magrath George | Chief Executive Officer | Shares withheld for tax | −75,541 | $5.97 | 2,048,485 | Form 4 |
| 8 September 2026 | Gallagher Cam | Director | Option exercise | +784,314 | $1.15 | 2,800,111 | Form 4 |
| 3 September 2026 | Gagnon Robert E. | Chief Financial Officer | Open-market sale | −28,000 | $4.54 | 556,375 | Form 4 |
| 23 July 2026 | Gagnon Robert E. | Chief Financial Officer | Open-market sale | −7,783 | $2.95 | 584,375 | Form 4 |
| 23 July 2026 | Magrath George | Chief Executive Officer | Open-market sale | −9,475 | $2.95 | 1,731,869 | Form 4 |
| 23 July 2026 | Schachle Joseph K | Chief Operating Officer | Open-market sale | −4,644 | $2.94 | 291,440 | Form 4 |
| 23 July 2026 | Yerxa Benjamin R | President | Open-market sale | −7,429 | $2.97 | 704,106 | Form 4 |
| 18 May 2026 | Foundation Fighting Blindness Retinal Degeneration Fund | Director | Open-market sale | −1,700,000 | $4.35 | 3,792,171 | Form 4 |
| 23 April 2026 | Gagnon Robert E. | Chief Financial Officer | Open-market sale | −7,842 | $5.18 | 592,158 | Form 4 |
| 23 April 2026 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Open-market sale | −7,542 | $5.19 | 509,233 | Form 4 |
| 23 April 2026 | Magrath George | Chief Executive Officer | Open-market sale | −9,511 | $5.22 | 1,741,344 | Form 4 |
| 23 April 2026 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Open-market sale | −1,641 | $5.20 | 188,671 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Opus Genetics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.